Zhi Tong Cai Jing·2025-08-21 23:39Group 1 - Tianjin Development (00882) announced that its indirect non-wholly-owned subsidiary, Lifesun Pharmaceutical (002393), plans to establish a fund with several partners, including Jianxin Equity and Teda Private Equity, with a proposed total subscription amount of RMB 500 million [1] - Lifesun Pharmaceutical intends to contribute RMB 174 million to the fund, representing 34.75% of the total proposed subscription amount [1] - The fund, tentatively named Jian Sheng Guo Xin Tai Da Equity Fund Partnership (Limited Partnership), is proposed to have a duration of five years and will primarily invest in the health and biotechnology sectors in China [1] Group 2 - The board believes that the potential transaction, if realized, will help the group deepen its understanding of the latest industry developments in the pharmaceutical sector, diversify investment risks, and identify potential strategic partners for future opportunities [1] - The board also considers that the investment in the fund could provide more industry acquisition opportunities aligned with the company's development strategy, offering potential returns beyond fixed income and improving capital allocation efficiency [1]